Xilio Therapeutics, Inc. (XLO)

Xilio Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	46.29	121.95	199.61	20.79	49.04
Cash & Cash Equivalents	46.29	121.95	199.61	20.79	49.04
Cash Growth	-62.04%	-38.91%	860.15%	-57.61%	-
Other Current Assets	1.84	2.55	2.91	-0.2	2.07
Total Current Assets	48.13	124.5	202.52	20.59	51.1
Property, Plant & Equipment	11.07	12.84	13.6	13.68	9.87
Other Long-Term Assets	1.73	1.83	1.95	2.05	1.75
Total Long-Term Assets	12.8	14.67	15.54	15.73	11.62
Total Assets	60.93	139.17	218.06	36.32	62.72
Accounts Payable	1.05	3.13	3.14	5.44	2.52
Current Debt	4.36	7.59	0.8	2.9	0
Other Current Liabilities	10.55	10.41	8.83	13.81	2.69
Total Current Liabilities	15.96	21.12	12.78	22.16	5.21
Long-Term Debt	8.14	12.35	19.74	18.32	18.63
Other Long-Term Liabilities	0	0.05	0.12	1.13	0.37
Total Long-Term Liabilities	8.14	12.4	19.85	19.45	19.01
Total Liabilities	24.1	33.52	32.63	41.6	24.21
Total Debt	12.5	19.94	20.54	21.22	18.63
Debt Growth	-37.29%	-2.91%	-3.21%	13.88%	-
Retained Earnings	-325.51	-249.11	-160.89	-85.09	-29.87
Shareholders' Equity	36.83	105.65	185.43	-83.29	-29.52
Net Cash / Debt	33.79	102.01	179.07	-0.43	30.41
Net Cash / Debt Growth	-66.88%	-43.03%	-	-	-
Net Cash Per Share	1.23	3.72	31.94	-0.82	7.82
Working Capital	32.17	103.38	189.74	-1.57	45.9
Book Value Per Share	1.34	3.86	33.08	-159.01	-7.59

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).